CompletedNot Applicable

Probability of Optimal Target Attainment of Amikacin in Patients With Febrile Neutropenia During Treatment for a Hematological Disorder

Switzerland92 participantsStarted 2022-12-21

Plain-language summary

The present trial is a single center, prospective, observational pharmacokinetics and pharmacodynamics (PKPD) cohort study investigating whether patients suffering from a hematological disorder and treated with amikacin due to febrile neutropenia (FN) achieve the predefined amikacin target concentration (Cmax ≥60 mg/L).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Informed consent (IC) as documented by signature * Documented hematological disorder * Hospitalization at the USB due to the treatment for a hematological disorder (e.g. chemotherapy, stem cell transplantation) * Being at risk of developing FN during the hospital stay (e.g. because of chemotherapy) Exclusion Criteria: * Previous enrolment into the current study * Outpatients * Patients undergoing hemodialysis * Women who are pregnant (special pharmacokinetic)

What they're measuring

Change in pharmacological target attainment (Cmax ≥60 mg/L) in blood during amikacin treatment

Timeframe: 60 minutes (+/-30 minutes) and 8 hours (+/-1 hour) after the beginning of amikacin infusion on day 1, day 2 and day 3

Trial details

NCT IDNCT05689450

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-02-02

View on ClinicalTrials.gov More Febrile Neutropenia (FN) trials